An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer (Q39859110)

15 September 2017

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer (English)

1 reference

15 September 2017

1 reference

Jacek Jassem

1 reference

15 September 2017

Rafal Dziadziuszko

1 reference

15 September 2017

Dara L Aisner

1 reference

15 September 2017

Marileila Varella-Garcia

series ordinal

object named as

Marileila Varella-Garcia

1 reference

15 September 2017

Robert C Doebele

1 reference

15 September 2017

D Ross Camidge

1 reference

15 September 2017

Anh T Le

1 reference

15 September 2017

Anna Wrona

series ordinal

1 reference

15 September 2017

8 April 2016

1 reference

Journal of Thoracic Oncology

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

1273-1281

1 reference

Activation of RAS family members confers resistance to ROS1 targeting drugs.

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Molecular pathways: ROS1 fusion proteins in cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Treating ALK-positive lung cancer--early successes and future challenges

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

The democratization of the oncogene

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4961521

Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27068398

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.JTHO.2016.04.001

1 reference

15 September 2017

1 reference

15 September 2017

PubMed publication ID

27068398

1 reference